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Abstract
Background: TrkA (encoded by NTRK1 gene), the high-affinity tyrosine kinase receptor for neurotrophins, is
involved in neural crest cell differentiation. Its expression has been reported to be associated with a favourable
prognosis in neuroblastoma. Therefore, the entire coding sequence of NTRK1 gene has been analysed in order to
identify mutations and/or polymorphisms which may alter TrkA receptor expression.
Methods: DNA was extracted from neuroblastomas of 55 Polish and 114 Italian patients and from peripheral
blood leukocytes of 158 healthy controls. Denaturing High-Performance Liquid Chromatography (DHPLC) and
Single-Strand Conformation Polymorphism (SSCP) analysis were used to screen for sequence variants. Genetic
changes were confirmed by direct sequencing and correlated with biological and clinical data.
Results: Three previously reported and nine new single nucleotide polymorphisms were detected. c.1810C>T
polymorphism present in 8.7% of cases was found to be an independent marker of disease recurrence (OR = 13.3;
p = 0.009) associated with lower survival rates (HR = 4.45 p = 0.041). c.1810C>T polymorphism's unfavourable
prognostic value was most significant in patients under 18 months of age with no MYCN amplification (HR = 26;
p = 0.008). In-silico analysis of the c.1810C>T polymorphism suggests that the substitution of the corresponding
amino acid residue within the conservative region of the tyrosine kinase domain might theoretically interfere with
the functioning of the TrkA protein.
Conclusions: NTRK1 c.1810C>T polymorphism appears to be a new independent prognostic factor of poor
outcome in neuroblastoma, especially in children under 18 months of age with no MYCN amplification.
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Background
Neuroblastoma (NB), a tumour of the peripheral nervous
system arising from embryonal neural crest cells (NCCs),
is the foremost malignant neoplasm of neonate and
infant [1]. It demonstrates considerable diversity in clini-
cal behaviour, ranging from spontaneous regression or
maturation to rapid progression despite aggressive ther-
apy [2]. Among molecular factors influencing the clinical
outcome of neuroblastoma, the expression of TrkA has
been associated with favourable prognosis [3].
TrkA is a member of a Trk family of tyrosine kinase recep-
tor for nerve growth factor (NGF) and other neuro-
trophins. TrkA primarily regulates growth, differentiation
and programmed cell death of neurons in both peripheral
and central nervous systems [4]. Formation of the neuro-
nal network during maturation of the peripheral nervous
system is a complex process that is rigorously governed by
the interactions of neurotrophins with their respective Trk
receptors [5]. Interestingly, TrkA expression may be
involved both in regulation of cell differentiation and in
induction of programmed cell death of NCCs sym-
pathoadrenal lineage. Consequently, alterations in the
genes of the Trk family may result in oncogenic transfor-
mation of the neural crest derivatives [6]. In NBs, the
amount of NGF in the tumour microenvironment and
expression of TrkA receptor has a profound effect on cel-
lular behaviour [7]. Tumour cells expressing TrkA undergo
cell differentiation in the presence of NGF [8], while with-
drawal of NGF induces apoptosis. Finally, as previously
reported, TrkA expression is a crucial factor for spontane-
ous regression of neuroblastoma [5].
Human TrkA coding gene (named NTRK1) maps to chro-
mosome 1q21-q22 and is composed of 17 exons [9,10].
Neither germ-line nor somatic gain-of-function muta-
tions of the NTRK1  gene have been observed in any
human neoplasia [11-15], except for one case of a de novo
AML. That patient was found to carry NTRK1  S677N
mutation that might interfere with the tyrosine kinase
(TK) activity [11]. A small number of polymorphisms of
unknown physiological significance has been reported in
a few cases of prostate cancer, papillary thyroid carcinoma
and NB [13-15]. Inborn inactivating mutations of NTRK1
gene are responsible for neurodevelopmental abnormali-
ties known as CIPA (Congenital Insensitivity to Pain with
Anhidrosis; MIM#256800), a rare recessive genetic disease
[16]. Interestingly, the clinical profile of CIPA does not
include predisposition to cancer.
Although many publications provide information on the
role of TrkA expression in NB [17], only one pilot study
analysed partially NTRK1  gene sequence in NBs [13].
Therefore, we performed mutational analysis of the entire
coding sequence of the NTRK1 gene to identify somatic
mutations and/or polymorphisms which might alter TrkA
expression and to evaluate clinical and biological conse-
quences of their incidence for the patients with NB.
Methods
Fifty-five NB patients treated in Polish paediatric onco-
logic centres and 114 NB patients retrieved from the Ital-
ian Neuroblastoma Group were enrolled into the study.
Main clinical and biological characteristics of the patients,
including age, stage of the disease, histology subtype in
accordance with International Neuroblastoma Pathology
Classification (INPC), MYCN  amplification status and
1p36 chromosome deletion, are shown in Table 1. A con-
trol group of 158 healthy anonymous adult volunteers
without history of hereditary cancer or other chronic dis-
orders was included into the study on the basis of a
detailed questionnaire and clinical examination. Written
informed consent was obtained from the relevant guardi-
ans of the children and from patients and controls them-
selves, whenever eligible. The study was approved by the
Ethics Committee of the Medical University of Gdańsk,
Poland.
DNA was extracted from fresh-frozen and/or paraffin-
embedded tumour samples obtained during initial sur-
gery procedures and from leukocytes of healthy controls.
Tumour DNA was analysed because peripheral blood
samples were not readily attainable from NB patients rep-
resenting a number of oncologic centres from two coun-
tries. After digestion with proteinase K, DNA was purified
by standard phenol-chloroform procedure [18]. All cod-
ing exons and flanking intronic (ca. 50 bp) sequences of
NTRK1 gene were screened for mutations using two com-
plementary techniques: SSCP (single-strand conforma-
tion polymorphism) analysis and DHPLC (denaturing
high performance liquid chromatography). SSCP was per-
formed in 12% polyacrylamide gels run at 200V for 2-4
hrs in 4°C followed by silver staining, as previously
described [15]. DHPLC was performed on an automated
WAVE System 3500 (Transgenomic Inc., San Jose, CA).
Samples showing variation in SSCP banding pattern and/
or abnormal profile of elution by DHPLC as well as a few
randomly selected negative samples were subject to
sequencing. DNA sequencing reactions were performed
using capillary-based ABI 3100 Genetic Analyser (Applied
Biosystems Inc., Foster City, CA).
Selected bioinformatic tools were used to assess the effect
of sequence variants on the structure and function of the
receptor. Alignment analysis of 4606 sequences similar to
TrkA retrieved from Pfam database [19] (as for 11.2008)
was used to identify conservative amino acid residues.
Protein Data Bank [20] (last accessed 11.2008) was
searched to identify the most structurally similar model of
the TK domain, which was later used as a template forBMC Cancer 2009, 9:436 http://www.biomedcentral.com/1471-2407/9/436
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construction of the TrkA homology model. The fold rec-
ognition methods were used https://genesilico.pl/meta2/.
The homology model was used to map mutated residues
onto the three-dimensional structure of a prototypical
kinase domain. Haplotype analysis of the entire NTRK1
gene sequence (chromosome 1q 155,097,295-
155,118,266) was performed using data representative for
the four distinct populations retrieved from International
HapMap Project database [21] (http://hap
map.ncbi.nlm.nih.gov/ last accessed 05.2008) using Hap-
loview software [22].
In all statistical analyses, allele frequencies were compared
between case and control subjects within each population
by chi-squared tests with adequate corrections, Fisher
exact probability tests with Freeman-Halton extension for
2 × 3 tables and in the two populations combined by the
Cochran-Mantel-Haenszel statistics. MAF (minor allele
frequency) <5% was the criterion for exclusion from fur-
ther statistical analysis. Unconditional logistic regression
was used to examine the association between NTRK1 gen-
otypes and clinical and biological characteristics of the
disease. The dichotomous NB prognostic risk factors used
as covariates are summarised in Table 1. The effect of the
genotypes on long-time survival rates were analysed using
Kaplan-Meier survival probability estimates, log-rank tests
and Cox hazard proportional models. In the analysis of
the two populations combined, an indicator variable for
the study population (Poland versus Italy) was added to
the models.
Results
Nine new NTRK1 gene variants were identified in NB sam-
ples. Four of them were located in the coding regions:
c.482G>A, c.505G>A in exon 5; c.1785G>A,
c.1858_1859delinsTC in exon 15 (Figure 1; Electronic
supplementary material - additional file 1). Besides, three
previously reported single nucleotide polymorphisms
(SNPs) were detected [15-17]: c.1674G>A(rs6334),
c.1810C>T(rs6336) and c.1887C>T(rs6337). (Figure 1;
Electronic supplementary material - additional file 2). A
nested study of the corresponding germline DNA con-
firmed presence of the SNPs at constitutional level.
For all non-synonymous variants (i.e. c.482G>A,
c.505G>A, c.1785G>A, c.1810C>T,
c.1858_1859delinsTC) in silico structure-function analy-
ses have been performed. c.482G>A codes the last residue
of the third leucine-rich motifs region. It is the last residue
of the α-helix and the replaced amino acid has similar
physical characteristics, thus the probability of its influ-
ence on protein structure is rather low. Similarly,
c.505G>A most likely does not affect the protein structure,
since it encodes a substitution of a residue in a non-struc-
turalised fragment of the protein. The remaining three
non-synonymous SNPs encode residues of the TK kinase,
among which residue 604 (coded by c.1810C>T) is the
only one evolutionarily conserved. We found an experi-
mentally determined structure of MuSK TK 1luf [23] to
have the highest similarity with the TrkA TK domain.
Sequence alignment revealed that all of the mutated TK
Table 1: Clinical and biological Features of Neuroblastoma Patients.
FACTOR Dichotomous covariate PL IT TOTAL
AGE ≤ 18 months of age 21 (38%) 76 (67%) 97 (57%)
>18 months of age 34 (62%) 38 (33%) 72 (43%)
STAGE 1, 2, 3, 4S 28 (51%) 88 (77%) 116 (69%)
4 27 (49%) 26 (23%) 53 (31%)
Histological subtype (INPC) FH 17 (31%) 20 (18%) 37 (22%)
UH 37 (67%) 88 (77%) 125 (74%)
unknown 1 (2%) 6 (5%) 7 (4%)
MYCN non-amplified 29 (53%) 92 (81%) 121 (72%)
amplified 20 (36%) 22 (19%) 42 (25%)
unknown 6 (11%) 0 6 (3%)
1 p del/imbalance 1 p normal 14 (25%) 52 (46%) 66 (39%)
1 p deletion/imbalance 22 (40%) 38 (33%) 60 (36%)
unknown 19 (35%) 24 (21%) 43 (25%)
Abbreviations: PL - Polish, IT - Italian group of patients; FH - favorable, UH - unfavorable histology: in accordance to International Neuroblastoma 
Pathology Classification (INPC)BMC Cancer 2009, 9:436 http://www.biomedcentral.com/1471-2407/9/436
Page 4 of 9
(page number not for citation purposes)
residues lie in the kinase insert (TrkA residues 602-622) at
the C-terminal lobe. This is a region of variable size and
unknown function in many receptor TKs [23]. Homology
modelling of TrkA TK domain, based on 1luf structure file,
allowed us to visualise the localisation of His604 relative
to the domain's functional regions (Figure 2).
Haplotype analysis of the NTRK1 gene revealed 12 tag
SNPs forming no haplotype blocks (Electronic supple-
mentary material - additional file 3). 2 of 12 tag SNPs
were exonic: c.1674G>A and c.1810C>T - and they were in
moderate linkage disequilibrium (Lewontin coefficient D'
= 1.0; LOD = 3.59; r2 = 0.165; 2.6 kb distance). The pres-
ence of such disequilibrium was confirmed by our exper-
imental data (D' = 0.568 [0.35-0.7]; LOD = 4.74; r2 =
0.094).
SNPs characterised by MAF>5% were further evaluated to
identify possible correlations with clinical and biological
prognostic markers of the disease. Results of Cochran-
Mantel-Haenszel analysis allowed the merging of data
coming from two (Polish and Italian) patient popula-
tions. For each SNP heterozygotes and minor allele
homozygotes were compared with major allele homozy-
gotes frequencies. Genotype distribution did not deviate
significantly from Hardy-Weinberg equilibrium. There
were no statistically significant differences in MAF
between patients and unaffected controls (Electronic sup-
plementary material - additional file 2). Association study
revealed no correlation between particular SNP and the
incidence of NB. Spearman rank correlation analyses
showed that none of the NTRK1 genotypes was associated
with the presence of any of the evaluated NB prognostic
markers. Logistic regression analyses identified
c.1810C>T polymorphism as an independent statistically
significant risk factor for disease recurrence (OR = 13.3;
95%CI: 1.9-94.0) along with MYCN amplification (OR =
9.79; 95%CI: 2.11-45.52) and clinical stage 4 (OR = 4.54;
95%CI: 1.08-19.1); p = 0.009.
Overall (OS) and event free (EFS) survival rates were ana-
lysed for each of the SNPs separately using log-rank tests
and Kaplan Meier plots. The presence of c.1810T allele
Sequence variants of the NTRK1 gene identified in the  present study Figure 1
Sequence variants of the NTRK1 gene identified in 
the present study. The structure of TrkA receptor. Extra-
cellular part of the protein consists of: two cysteine clusters 
(Cys); three leucine-rich motifs (LRM) and two immunoglob-
ulin-like C2 domains (Ig-C2). It is followed by a short trans-
membrane portion (TM), and intracellular juxtamembrane 
domain (JM) and tyrosine kinase domain (TK). * - newly iden-
tified sequence variants, circled - the SNPs having MAF 
(minor allele frequency) value >5%, arrows - exonic localiza-
tion of the variants, dishes - intronic localization of the vari-
ants.
Homology model of the TrkA TK domain Figure 2
Homology model of the TrkA TK domain. The model 
was obtained using rat MuSK kinase structure 1luf [23]. Acti-
vation loop (orange) and catalytic loop (blue) are indicated in 
accordance to de Pablo et al. [31]. The kinase insert fragment 
of kinase domain constitutes a loop joining two alpha-helices. 
Most of its residues are missing in the crystal structure pre-
sumably due to the loop's high conformational flexibility and 
therefore not present in homology model (depicted as green 
beads). The His604 residue (red) is located at the end of 
structurally determined helical region, distant from ATPase 
active site (arrow). It may, however, be involved in interac-
tions with residues of the unstructured loop region. 
Although the function of this loop is not yet known, it may be 
speculated that it is involved in specific for TrkA interactions 
with secondary messengers or regulatory proteins. Homol-
ogy model was visualized with VMD program [32].BMC Cancer 2009, 9:436 http://www.biomedcentral.com/1471-2407/9/436
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was associated with shorter survival rates (Figure 3). Five-
year OS for c.1810CC was 77.6% (95%CI: 68.6-86.6) v.
26.3% (95%CI: 0-66.8) for c.1810CT and c.1810TT (p =
0.020); while 5-year EFS were 73.8% (95%CI: 64.5-83.1)
and 26.3% (95%CI: 0-66.8) (p = 0.047), respectively.
Inferior survival rates related to the presence of c.1810T
allele were even more evident in the group of children
under 18 months of age and without MYCN amplification
(Figure 3C, D). Here, 5-year OS was 89.2% (95%CI: 80.4-
98.0) v. 33.3% (95%CI: 0-83.2) p = 0.0015; while 5-year
EFS were 86.9% (95%CI: 77.8-96.0) and 33.3% (95%CI:
0-83.2) p = 0.0067, respectively.
The results of univariate analyses were further confirmed
by Cox proportional hazard analysis. Firstly, a model
inclusive of NTRK1 genotypes and adjusted for classical
risk factors (7 variables - Table 2) was assessed. Three
parameters were found to be significantly associated with
shorter OS, comprising c.1810T allele having HR = 4.54
(95%CI: 1.07-19.3) at p = 0.041 (overall level of signifi-
cance of the Cox model p = 0.00016). In the second step,
backward elimination of features aimed at identification
of minimal set of parameters predictive for OS was per-
formed. This further confirmed c.1810T allele to be a sig-
nificant marker of inferior OS, along with MYCN
amplification and patient's age. Inclusion of the informa-
Kaplan-Meier estimates of 5-year OS (A) and EFS (B) for NB patients and 5-year OS (C) and EFS (D) for NB patients under 18  months of age and without MYCN amplification with respect to c.1810C>T polymorphism Figure 3
Kaplan-Meier estimates of 5-year OS (A) and EFS (B) for NB patients and 5-year OS (C) and EFS (D) for NB 
patients under 18 months of age and without MYCN amplification with respect to c.1810C>T polymorphism. 
Figures A and B show results for the entire group of NB patients (n = 145): 133 patients with NTRK1 c.1810CC genotype and 
12 cases with NTRK1 c.1810CT/c.1810TT genotype. Figures C and D show results for the group of NB patients under 18 
months of age and without MYCN amplification (n = 84). This subgroup consists of 78 patients with NTRK1 c.1810CC geno-
type and 6 cases with NTRK1 c.1810CT/c.1810TT genotype.BMC Cancer 2009, 9:436 http://www.biomedcentral.com/1471-2407/9/436
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tion on stage of the disease did not improve the model
(data not shown). This finding is probably due to a strong
association of stage and MYCN  amplification (43% of
patients with stage 4 harboured MYCN amplification in
their tumours versus only 22% of patients with earlier
stages; p = 0.001 by Fisher's exact test) and a strong asso-
ciation between stage and age <18 months (25% of
patients with stage 4 were under 18 months versus 72% of
patients with earlier stages; p = 0.006 by Fisher's exact
test). We did not observe an association between MYCN
amplification and c.1810T allele (p = 1.00 by Fisher's
exact test) or between age and c.1810T allele (p = 1.00 by
Fisher's exact test).
Besides, in the group of patients under 18 months of age
and without MYCN amplification, c.1810T was found to
be the only independent prognostic parameter with HR =
26 (95%CI: 2.01-339); p = 0.008.
Discussion
The basic alteration in NB is developmental arrest of neu-
ronal differentiation and unrestricted proliferation that
most probably result from altered expression of genetic
factors. Studies of familial cases of NB allowed for identi-
fication of two NB susceptibility genes (ALK, PHOX2B)
yet their mutations are present in about 10% of sporadic
tumours [24,25]. Inability to identify a single major spe-
cific tumour suppressor gene as a triggering agent of NB
initiation [2] points toward the role played by genes
involved in normal noradrenergic development. NTRK1
gene encoding TrkA neurotrophin receptor for NGF, is
referred to as a candidate predisposition gene [5]. In this
study, we investigated the genetic variability at the NTRK1
locus in human NBs.
Previously, only one study analysed sequence of NTRK1
gene in NBs [13] and that analysis was limited to the
region coding TK domain (exons 13-16). This and two
other studies of the NTRK1 sequence: in prostate cancer
[15] and medullary thyroid carcinoma [14], utilised SSCP
as the sole screening method. However, current standards
of molecular diagnostics do not recommend SSCP as a
single screening procedure for detection of sequence vari-
ants because of its low sensitivity of 50-86%, while
DHPLC is considered to be the method of choice because
of its sensitivity exceeding 99% [26]. In our study, we used
both methods. DHPLC vastly outperformed SSCP, allow-
ing for detection of a notably larger number of sequence
variants (11/12 versus 5/12 SNPs identified).
Although TrkA expression in NBs was reported signifi-
cantly variable even at the cellular level within a single
case [27], the genetic variability at the NTRK1 gene locus
was found to be very limited. Non-synonymous polymor-
phisms were detected in less than 10% of the analysed
cases. Furthermore, tag SNPs identified by HapMap
project as well as SNPs present in NCBI dbSNP in vast
majority are located in the intronic sections of the gene or
do not result in amino acid substitution. Besides, accord-
ing to the results of bioinformatic analyses, the identified
non-synonymous polymorphisms, with the exception of
c.1810C>T, have minimal theoretical chance of affecting
the protein's structure and/or functions. These findings
confirm the conservative character of NTRK1  gene
Table 2: Significance of the NTRK1 genotypes of MAF>5% and clinical and biological features of the disease on long-time OS rates 
assessed by multivariate Cox hazard regression model (overall significance of the model at p = 0.00016).
Feature HR 95%CI p value
(Wald statistics)
Age ≤18 months 0.22 0.07-0.70 p = 0.010
MYCN amplification 3.47 1.11-10.8 p = 0.032
NTRK1 c.1810T allele 4.54 1.07-19.3 p = 0.041
unfavorable histology 3.01 0.67-13.4 p = 0.149
chromosome 1 p deletion/imbalance 1.44 0.46-4.46 p = 0.531
NTRK1 c.1887T allele 0.69 0.15-2.99 p = 0.619
NTRK1 c.1674A allele 1.21 0.43-3.43 p = 0.714
Stage 4 1.15 0.42-3.14 p = 0.789
HR - hazard ratio; CI - confidence intervalsBMC Cancer 2009, 9:436 http://www.biomedcentral.com/1471-2407/9/436
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sequence; however, it is possible that significant sequence
variants are located elsewhere, for instance in currently
unknown 3' flanking regulatory elements.
Even though c.1810C>T has MAF of 6%, from compre-
hensive statistical analysis of the associations with NB
clinical and biological prognostic factors it appears to be
an independent unfavourable risk factor in NB patients.
c.1810T allele has been detected in 8.7% of sporadic
tumours, which is a similar frequency to the mutations
observed for the two known familial NB susceptibility
genes (ALK = 12.4%, PHOX2b = 4.3%) [24,25]. Presence
of c.1810T allele correlated with inferior 5-year OS and
EFS and with more frequent relapse of the disease. From
the analyses of the Cox hazard regression models, it
appears that c.1810T provides additive information to
MYCN amplification status and age of the patient, allow-
ing for finest prediction of the eventual outcome of the
disease. Interestingly, the stage of the disease was less
informative and could be omitted in the model based on
minimal set of predictive parameters. The lack of prognos-
tic significance of stage is most probably due to strong
associations with other prognostic variables - MYCN
amplification and age. These associations were not
observed for the NTRK1 c.1810C>T polymorphism.
The additive value of c.1810T allele to the current clinical
prognostic markers should be, however, assessed on a
prospective, more coherent, group of patients. In the cur-
rent study, patients were enrolled in two countries over 20
years, thus they received a range of treatment protocols.
Also, histopathological assessment was modified over the
time and not all the samples could be assessed in accord-
ance with the revised INPC. Interestingly, IT patients were
diagnosed with lower stages of the disease and at a
younger age, which is most probably related to better
access to medical imaging techniques in Italy and thus
higher incidence of incidentalomas diagnosed before
overt clinical symptoms of advanced disease became
apparent. The above-presented discrepancy in the patient
population and the fact that the study was retrospective
might, however, result in some limitation of the force of
the study.
The mechanisms through which c.1810T variant could
trigger and/or modify oncogenic events in embryonal
NCC are only hypothetical at this time; however, our pre-
liminary data provide an interesting starting point for fur-
ther studies, possibly using a genome-wide association
methodology.
Several points strongly support the significance of our
finding; a) first, the evidence of the observed correlations
was highly significant, both in univariate and multivariate
analyses. Similarly, in the previous study of 63 NBs [13],
there was a trend for the c.1810T to be present in cases
having advanced stages of the disease; b) there were no
major differences in allelic frequencies among two Euro-
pean populations that would explain these findings on
the basis of population stratification. Linkage disequilib-
rium between c.1674G>A and c.1810C>T was present in
both groups of patients, and also in four populations
from HapMap database, thus the results obtained in both
patient groups most probably refer to the same genetic
effect; c) the bioinformatic analysis of the c.1810C>T
showed that substitution of the corresponding amino acid
(His→Tyr) affects a conservative residue of the TK
domain. This substitution changes the chemical proper-
ties of a residue in conserved position, which may possi-
bly alter the function of TK domain. From analysis of our
homology model as well as from the results of in vitro
studies by Mardy et al. [28], it appears that c.1810C>T
does not inhibit the ability for autophosphorylation of TK
domain. It may, however, be involved in interactions with
the residues of the kinase insert loop. The exact role of this
fragment of TK, specific for TrkA, remains unknown
though it may be involved in signal transduction through
interfering with the adaptor molecules.
Finally, a few methodological considerations regarding
peculiarities of gene association studies performed on a
paediatric oncologic experimental group should be
pointed out. The relatively low incidence of neuroblast-
oma of 10.9 cases per million children yearly [29] affects
the available size of patient sample group. In order to
overcome this limitation, patients representing two Euro-
pean populations were enrolled in the study after initial
validation of their correspondence using the Cochran-
Mantel-Haenszel analysis. Another important methodo-
logical issue is related to the design of an adequate control
group. If age-matched child controls had been used in the
study, a screening for clinically inert tumour would have
been required, however this might have created an ethical
dilemma. Therefore, similarly to other studies in the field
[30], healthy adult volunteers were chosen as controls,
even if such a decision was related to some decrease in the
force of the study. Moreover, even though the study was
aimed at detection of constitutional mutations, since the
available material collected by both national tissue banks
consisted of primary NB tumours, tumour DNA was ana-
lysed. A similar approach is applied in studies of other
researchers [24,25] because tumour biology is the area of
primary interest from the clinical point of view. Besides,
tumour samples are the routine material available for
molecular assessment in research setting. Nevertheless,
supplementary nested study of the corresponding germ-
line DNA, derived from peripheral blood leukocytes of
the cases where such material was available, was per-
formed to provide confirmation of the constitutional
character of the analysed SNPs.BMC Cancer 2009, 9:436 http://www.biomedcentral.com/1471-2407/9/436
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Conclusions
We propose NTRK1 c.1810C>T polymorphism as a new
prognostic factor in NB. In contrast to known NB suscep-
tibility genes (ALK and PHOX2b), NTRK1 c.1810C>T pol-
ymorphism does not predispose to NB development.
Conversely, its presence confers worse prognosis to the
affected patients. Nevertheless, further studies are needed
to disclose its effect on TrkA receptor structure and/or
function, for instance by comparing the expression levels
of wild type and mutated TrkA at RNA and protein levels.
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